Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0015672 (fatigue)
 51,768 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The clinical effects are reported of the benzodiazepine derivative, bromazepam (Lexotanil) in the treatment of psychosomatic disorders in the course of neurotic, psychovegetative, and masked depressive syndromes. The drug was administered orally in 301 patients (178 males, and 123 females). Target symptoms were anxiety, tension, and varied organic dysfunction of psychogenic origin. The optimum daily dosage was three times 3 mg; the duration of treatment ranged from 1 week to 34 months. The effect of treatment was considered excellent in 51.5%, good in 42.5%, moderate in 2%, and absent in 4%. The most responsive target symptoms were psychogenic disorders of the cardiovascular system and of the gastrointestinal tract, as well as anxiety, while no true antidepressive effect was observed. Drug tolerance is excellent. Slight fatigue, vertigo or a mild reduction in psychomotor activity were complained of by about 10% of the patients and usually occurred with daily doses of 18 mg or more, whereas no other side effects were observed. There was no obvious tendency to drug dependence even after after long-term treatment of up to 34 months. Bromazepam appears to be a superior compound to other anxiolytic and psychovegetatively active minor tranquillisers on account of its mild hypnotic action. Its anxiolytic effect causes additional indirect sleep induction in the above-mentioned conditions.
 ...
PMID:[Bromazepam in the treatment of somatized psychogenic disorders (author's transl)]. 3 34

Bromazepam was compared with placebo and with chlorprothixene in a randomized, double-blind group-comparative multicenter trial in general practice. Two hundred and forty-five patients with generalized anxiety disorder (DSM-III 1980) were treated for 2 weeks with two daily doses of bromazepam, 3 mg or chlorprothixene, 15 mg or placebo. Median reductions in Hamilton Anxiety rating were 12 (bromazepam), 10.3 (chlorprothixene) and 7.3 (placebo). The study revealed significant superiority of bromazepam over placebo (median differences 3.3, 95% confidence limits: 0.3 and 6.1) but not over chlorprothixene (median difference 1.4, 95% confidence limits -0.8 and +3.5). Significantly higher rates of tiredness, sedation and hypersomnia were found on bromazepam and chlorprothixene compared to placebo. Tolerance was rated as "at least good" in 85.6% on bromazepam, in 86% on chlorprothixene and in 87.8% on placebo. Neither previous psychopharmacological treatment nor presence of psychosocial stress were of perceptible influence. Bromazepam and chlorprothixene are both superior to placebo in generalized anxiety states treated in general practice, but spontaneous improvements/placebo effects are substantial.
 ...
PMID:Bromazepam in generalized anxiety. Randomized, multi-practice comparisons with both chlorprothixene and placebo. 196 72

An open trial of bromazepam (Lexomil) was conducted in 35 patients (23 men and 12 women, aged from 18 to 76 years) admitted to a psychiatry unit for various, usually old-standing, conditions associated with major anxiety. The mean effective dosage was 18 mg/day. The effectiveness of the drug administered alone was assessed in 25 patients at the end of the second week of treatment, using the Hamilton and Pull-Guelfi scales. A satisfactory response was obtained in 81% of the cases. Reactional anxiety in alcoholic and neurotic patients was found to constitute the best indication for bromazepam, the value of which during weaning from alcohol in patients admitted with threatening delirium tremens must be stressed. Bromazepam was well tolerated in 83% of the patients; side-effects (daytime somnolence and fatigue) were rare. The drug proved a potent and quick-acting tranquillizer and often resulted in a shorter stay in hospital.
 ...
PMID:[Clinical trial of bromazepam in psychiatric hospital practice (author's transl)]. 612 35